Pharmaceutical Report Library l Report Store l Pharma Intelligence

Nucala

Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.

July 31, 2018

Find out more

U.S. Markets for Orthopedic Extremity and Soft Tissue Repair, September 2015

$5,250.00

The United States (U.S.) market for orthopedic extremity and soft tissue repair products encompasses interventional surgical procedures and biologic and synthetic implants used in the repair of bone, joints, and soft tissue that have been damaged as a result of disease or due to physical injury.

September 1, 2015

Find out more

Fitusiran

Alnylam, in conjunction with its development partner Sanofi, is developing fitusiran for the treatment of hemophilia A and B.

May 4, 2018

Find out more

Big Pharma Licensing Trends, 2012–16

$2,995.00

Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.

March 8, 2017

Find out more

Seviprotimut-L

Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.

May 23, 2018

Find out more

Disease Analysis: Type 2 Diabetes

Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.

October 20, 2021

Find out more

Januvia

Januvia (sitagliptin; Merck & Co) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

November 7, 2017

Find out more

Oncology: Surgical Ablation Devices Market

$4,750.00

Valued at approximately $380m in 2017, the Surgical Ablation Devices Market for Oncology is expanding at a double-digit rate, driven by the increasing global prevalence of cancer and the growing demand for better healthcare in emerging markets.

June 19, 2018

Find out more

Market Spotlight: Cold Agglutinin Disease

$1,318.00

Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.

November 29, 2021

Find out more

Tresiba

Tresiba (insulin degludec; Novo Nordisk) is an ultra-long-acting basal insulin analog approved for the treatment of type 1 and type 2 diabetes in Japan and Europe since October 2012 and January 2013, respectively.

November 7, 2017

Find out more

Singulair

Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.

February 16, 2018

Find out more

Disease Analysis: Meningococcal Vaccines

Meningococcal meningitis is caused by the bacteria Neisseria meningitidis, which causes a serious infection to the lining surrounding the brain and spinal cord. In all, 12 known serogroups of Neisseria meningitidis have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics. The Centers for Disease Control and Prevention (CDC) has reported around 1 in 10 people are asymptomatic carriers of the bacteria.

January 10, 2022

Find out more

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Find out more

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

January 8, 2019

Find out more

Xeljanz

While Xeljanz (tofacitinib; Pfizer/Takeda) demonstrated positive efficacy in its Phase III clinical trial

program, its future in psoriasis is uncertain.

October 17, 2017

Find out more

NASH KOL Insight Interview #2

$599.00

KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

March 4, 2014

Find out more

NovoEight

NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.

May 4, 2018

Find out more

Market Spotlight: Gastrointestinal Stromal Tumor (GIST)

$1,318.00

This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.

November 5, 2021

Find out more

Tecentriq

Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.

February 26, 2020

Find out more

GLP-1 Pulse Survey

$599.00

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

$599.00

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

Bladder Cancer Pricing, Reimbursement, and Access

$2,995.00

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.

September 27, 2018

Find out more

Victoza

Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.

July 7, 2017

Find out more

Masitinib

Masitinib (AB Science) is designed to selectively inhibit the receptor tyrosine kinase c-Kit, as well as select angiogenic growth factor receptors, specifically platelet-derived growth factor receptor and fibroblast growth factor receptor.

May 23, 2018

Find out more

Post-EASL KOL Insight Interview

$599.00

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Q3 2021 Outlook Report

$4,750.00

In this report, we cover catalysts from 27 drugs, devices, diagnostics, and deals expected to occur in the third quarter of 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

June 2, 2021

Find out more

Disease Analysis: HIV Treatment

HIV, or the human immunodeficiency virus, is a lentivirus belonging to the Retroviridae family. HIV infects and destroys cells of the immune system, including cluster of differentiation 4+ (CD4+) T cells, macrophages, and dendritic cells, progressively impairing the infected individual’s ability to respond to subsequent infections. If left untreated for several years, the continued destruction of CD4+ T cells can lead to the development of acquired immunodeficiency syndrome (AIDS) (defined as a CD4+ T-cell count <200 cells/mm3), which is characterized by increased susceptibility to opportunistic infections and cancers. Although HIV infection is currently incurable, there are several effective highly active antiretroviral therapies (HAARTs) available that can suppress viral replication and prevent the progression of infection to AIDS.

October 29, 2021

Find out more

Blincyto

Blincyto, produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant B-cells. It activates endogenous T-cells by connecting…

October 9, 2018

Find out more

U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunites in the benign uterine condition therapy systems market, including global endometrial ablation systems, MR-guided focused ultrasound systems, uterine artery embolization systems, and hysteroscopes/fibroid removal systems.

November 14, 2015

Find out more

Report library

Nucala

U.S. Markets for Orthopedic Extremity and Soft Tissue Repair, September 2015

Fitusiran

Big Pharma Licensing Trends, 2012–16

Seviprotimut-L

Disease Analysis: Type 2 Diabetes

Januvia

Oncology: Surgical Ablation Devices Market

Market Spotlight: Cold Agglutinin Disease

Tresiba

Singulair

Disease Analysis: Meningococcal Vaccines

Alzheimer’s KOL Interview

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

Xeljanz

NASH KOL Insight Interview #2

NovoEight

Market Spotlight: Gastrointestinal Stromal Tumor (GIST)

Tecentriq

GLP-1 Pulse Survey

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

Bladder Cancer Pricing, Reimbursement, and Access

Victoza

Masitinib

Post-EASL KOL Insight Interview

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

Q3 2021 Outlook Report

Disease Analysis: HIV Treatment

Blincyto

U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies